Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a detailed update on evolving incretin-based therapies, with a primary focus on a significant formulation change for tirzepatide.

Key Episode Timestamps
00:00:01 Intro
00:00:11 Zepbound in the KwikPen
00:01:25 Vials versus pens
00:02:55 Environmental benefits
00:03:53 Pen needles sold separately
00:06:30 LillyDirect availability
00:07:20 Europe approves 7.2 mg injectable semaglutide
00:09:08 Reusable pen concerns
00:10:55 Outro